Author

I. Berestjuk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

M. Deckert· 3 shared M. Lecacheur· 3 shared S. Diazzi· 3 shared S. Tartare-Deckert· 3 shared A. Mallavialle· 2 shared C. Gaggioli· 2 shared C. Girard· 2 shared C. Rovera· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Deckert

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Myeloid mechano-metabolic programming restricts anti-tumor immunity

K. Tharp, K. Kersten, O. Maller, G. Timblin, C. Stashko, F. Canale, M.-K. Hayward, I. Berestjuk, J. ten Hoeve-Scott, B. Samad, R. Geiger, A. Combes, V. Weaver

This study shows that fibrotic tumor microenvironments impair anti-tumor immunity through myeloid cell-driven metabolic changes that hinder CD8+ T cell function.

bioRxiv · Jul 14, 2022 · PreprintCancer Biology

Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanoma

S. Diazzi, A. Baeri, J. Fassy, M. Lecacheur, O. Marin-Bejar, C. Girard, L. Lefevre, C. Lacoux, M. Irondelle, C. Mounier, M. Truchi, M. Couralet, A. Carminati, I. Berestjuk, F. Larbret, , S. Tartare-Deckert

This study identifies the miR-143/-145 cluster as a driver of therapy-resistant mesenchymal-like phenotype in melanoma and shows that blocking its pro-fibrotic effects enhances MAPK inhibitor efficacy.

bioRxiv · Jul 2, 2021Cancer Biology

Invasive dedifferentiated melanoma cells inhibit JAK1-STAT3-driven actomyosin contractility of human fibroblastic reticular cells of the lymph node

C. Rovera, I. Berestjuk, M. Lecacheur, S. Diazzi, A. Mallavialle, J. Albrengues, C. Gaggioli, C. C. Girard, T. Passeron, M. Deckert, S. Tartare-Deckert, V. Prod'homme

The paper shows that dedifferentiated melanoma cells inhibit FRC contractility via JAK1-STAT3 and YAP pathways, reducing actomyosin forces and promoting LN remodeling.

bioRxiv · Mar 25, 2021 · PreprintCancer Biology

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapy

S. Tartare-Deckert, I. Berestjuk, M. Lecacheur, S. Diazzi, C. Rovera, V. Prod'homme, A. Mallavialle, F. Larbret, S. Pisano, S. Audebert, T. Passeron, C. Gaggioli, C. Girard, M. Deckert

This study shows that targeting DDR1 and DDR2 overcomes matrix-mediated resistance to BRAF inhibitors in melanoma by disrupting ECM-driven survival pathways.

bioRxiv · Nov 28, 2019 · PreprintCancer Biology